The complexity of this undertaking highlights a fundamental enforcement reality. If it’s this hard for regulators to demonstrate why a patently worrisome acquisition should be blocked, it is even less likely that they will investigate or attempt to halt mergers for which potential effects are unclear. […]
Consolidation will surely continue before we can determine whether it is benign.
– Leemore Dafny, The New England Journal of Medicine